Novo Nordisk stock climbs as investors await August earnings and dividend

Novo Nordisk shares rose 2.6% to $50.96, outperforming the S&P 500 and other major indices. Analysts are focusing on the company’s upcoming earnings release, for which the Zacks consensus projects earnings per share of $0.82 and net sales of $11.27 billion – both lower than a year earlier. The firm also faces an ex‑dividend date slated for mid‑August, with the dividend amount and timing still to be confirmed.

In the most recent quarter, adjusted revenue fell 4% and operating profit slipped 6%, yet management slightly raised its 2026 outlook, citing strong demand for its oral obesity drug Wegovy, which has already exceeded two million prescriptions in the United States. The stock’s price‑to‑earnings multiple sits around 16, and valuation metrics suggest further upside if the earnings beat expectations.

Investors will watch the August results closely to see whether the sales volume of Wegovy and other products can offset the revenue decline and support a higher dividend or a price move toward the psychologically important €50 level.